<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425698</url>
  </required_header>
  <id_info>
    <org_study_id>MHH - EPONTX - 01/06</org_study_id>
    <nct_id>NCT00425698</nct_id>
  </id_info>
  <brief_title>Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation</brief_title>
  <official_title>Effect of Erythropoietin on Renal Function After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death
      and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury.
      Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue
      damage and loss of renal function after successful kidney transplantation in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erythropoietin (EPO) has pleiotropic effects well beyond the maintenance of red blood cell
      mass. In the embryo, EPO is a major regulator of vascular formation and organ growth, and EPO
      receptors are found in almost every embryonic tissue. EPO receptors also exist in many adult
      tissues including renal tissue, and even the notion of autocrine or paracrine EPO systems has
      been raised. Although the peritubular fibroblasts are the major adult site for EPO
      production, EPO receptors have been demonstrated in many kidney cell types, e.g. proximal
      tubule epithelial cells, mesangial cells, and the glomerulus. Moreover, EPO has important
      cytoprotective effects on various cell lines and organs, and protection from ischemic injury
      and inhibition of apoptotic death-related pathways has been reported in brain, heart and
      renal tissue. The intracellular pathways involved in these favourable EPO effects may involve
      nuclear translocation of the transcription factor NF- B, JAK2 phosphorylation and
      phosphorylation of Akt (protein kinase B).

      A recent experimental study revealed that cobalt administration to rats caused up-regulation
      of EPO, and diminished the degree of renal injury caused by ischemia-reperfusion (I/R),
      suggesting that EPO may also play an important role in renal ischemic preconditioning.
      Indeed, subsequent studies from different laboratories demonstrated that preconditioning with
      recombinant human EPO (rHuEPO) is protective against I/R injury in rodents. In this respect
      data on specific protective effects of rHuEPO and its analogues on endothelial cells of
      glomeruli are of particular interest. Furthermore, administration of rHuEPO may not have only
      protective effects on the vascular level, but also potential of regeneration, since EPO also
      stimulates proliferation and differentiation of regenerative cells such as endothelial
      progenitor cells (EPCs).

      Renal ischemia, whether caused by shock or after surgery, is a major cause of acute renal
      failure (ARF) in man. In this respect kidney transplantation is a classical model of ARF due
      to I/R injury, since the transplanted organ is connected to the recipients blood supply
      usually after several hours of &quot;cold ischemia&quot;. Although reperfusion is essential for the
      survival of ischemic tissue, it also initiates a complex and interrelated sequence of events
      that results in injury and the eventual death of renal cells as a result of a combination of
      both apoptosis and necrosis. Apoptotic cell death has been documented in human biopsies after
      renal I/R, and inhibition of apoptotic signalling and cell death ameliorates the associated
      injury and inflammation in an experimental model of ischemic ARF. Similarly, I/R damage of
      transplanted kidney is thought to be a major factor limiting renal function after successful
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>42 days after transplantation</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>6 month after transplantation</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>intravenous erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant erythropoietin alpha (rHuEPO alpha)</intervention_name>
    <description>Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation</description>
    <arm_group_label>intravenous erythropoietin</arm_group_label>
    <other_name>Erypo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation</description>
    <arm_group_label>intravenous erythropoietin</arm_group_label>
    <arm_group_label>intravenous placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Male or female aged 18 to 70 years without restricted legal competence and being able
             to follow the trial instructions

          3. Cadaveric renal transplant, cold ischemia time below 24 h, and standard
             immunosuppressive regimen

          4. A haemoglobin level &gt; 8 and &lt; 14 g/dl

          5. Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF
             or azathioprine)

          6. In patient with diabetes mellitus HbA1c &lt; 9%

        Exclusion Criteria:

          1. Previous or current myelodysplastic or -proliferative disorders

          2. History of cancer within the last 5 years.

          3. Systemic chemotherapy or radiotherapy

          4. Higher degree renal anemia or persistent Hb &gt; 14 g/dl

          5. Treatment with other stem cell growth factors cells like GM-CSF, VEGF

          6. Bleeding episodes within 3 month prior transplantation

          7. Sitting diastolic BP &gt; 110 mmHg or sitting systolic BP &gt; 170 mmHg

          8. Known intolerance of rHuEpo or analogs

          9. Cardiovascular event within 6 months prior transplantation

         10. Thromboembolic event within 6 months prior transplantation

         11. Relevant stenosis of extra- and intracranial, and peripheral arteries

         12. Systemic diseases (SLE or vasculitis)

         13. Acute or chronic infection and/or CRP &gt; 10 mg/l prior transplantation

         14. Hemolysis or disorders of blood formation (e.g., thalassemia)

         15. Further organ transplants or combined organ transplantation

         16. Pregnancy or inadequate contraception

         17. Psychiatric or emotional problems, or chronic seizures

         18. Unwillingness to participate satisfactorily for the entire trial period

         19. Participation in a clinical trial within 30 days prior to study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danilo Fliser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2007</study_first_posted>
  <results_first_submitted>August 4, 2010</results_first_submitted>
  <results_first_submitted_qc>September 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2010</results_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Danilo Fliser, MD, Professor of Medicine</name_title>
    <organization>Saarland University Medical Centre</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February 2007 until May 2009. Single recruitment site was the Hannover Medical School in Hannover, Germany</recruitment_details>
      <pre_assignment_details>420 patients screened, 88 patients finally enrolled, other patients not enrolled because of age&lt;18 years, living-related kidney transplantation, high pre-immunisation, multiple transplantation, participation in other studies, no interest for participation or withdraw of consent</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Erythropoietin</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erythropoietin</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="2"/>
                    <measurement group_id="B2" value="50" spread="2"/>
                    <measurement group_id="B3" value="52" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation</description>
        <time_frame>42 days after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erythropoietin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="28"/>
                    <measurement group_id="O2" value="46" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Erythopoietin significantly improves kidney graft function. Power calculation: with a difference of at least 4 mL/min in mean eGFR between groups the number of patients enrolled per group (at least 41) would allowed the detection of a significant difference between groups at a 5% level (p&lt;0.05)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation</description>
        <time_frame>6 month after transplantation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erythropoietin</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>graft loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Danilo Fliser</name_or_title>
      <organization>Saarland University Medical Centre</organization>
      <phone>(49) 6841 ext 1623526</phone>
      <email>indfli@uks.eu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

